ENSC Ensysce Biosciences, Inc. - 8-K

Item
3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing

On
May 21, 2026, Ensysce Biosciences Inc. (the “ Company ”) received notice from the Listing Qualifications Department
of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that due to the Company’s non-compliance with the $2.5 million
stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026, the Company is subject to delisting
unless it submits a plan within 45 days (by July 6, 2026) to regain compliance. If the plan is accepted, the Company may be granted an
extension of up to 180 days from May 21, 2026, to regain compliance. If the plan is not accepted, the Company may appeal to the Nasdaq
Hearings Panel (the “Panel”). The Company plans to submit timely a plan to Nasdaq.

The
Company intends to actively explore options to regain compliance with Nasdaq listing requirements; however, there can be no assurance
that Nasdaq will accept the Company’s plan to regain compliance or that, if the plan is not accepted and the Company appeals, the
Panel will accept the plan or that the Company will be able to evidence compliance prior to the expiration of any extension that may
be granted to the Company.

2